FI3688027T3 - Mutatoidun p53:n tunnistavia t-solureseptoreita - Google Patents

Mutatoidun p53:n tunnistavia t-solureseptoreita

Info

Publication number
FI3688027T3
FI3688027T3 FIEP18780006.5T FI18780006T FI3688027T3 FI 3688027 T3 FI3688027 T3 FI 3688027T3 FI 18780006 T FI18780006 T FI 18780006T FI 3688027 T3 FI3688027 T3 FI 3688027T3
Authority
FI
Finland
Prior art keywords
amino acid
seq
acid sequence
tcr
cancer
Prior art date
Application number
FIEP18780006.5T
Other languages
English (en)
Finnish (fi)
Inventor
Steven A Rosenberg
Winifred M Lo
Yong-Chen Lu
Maria R Parkhurst
Paul F Robbins
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of FI3688027T3 publication Critical patent/FI3688027T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FIEP18780006.5T 2017-09-29 2018-09-17 Mutatoidun p53:n tunnistavia t-solureseptoreita FI3688027T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29
PCT/US2018/051285 WO2019067243A1 (en) 2017-09-29 2018-09-17 T CELL RECEPTORS RECOGNIZING P53 MUTE

Publications (1)

Publication Number Publication Date
FI3688027T3 true FI3688027T3 (fi) 2025-12-09

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18780006.5T FI3688027T3 (fi) 2017-09-29 2018-09-17 Mutatoidun p53:n tunnistavia t-solureseptoreita

Country Status (20)

Country Link
US (2) US11939365B2 (https=)
EP (2) EP4647442A3 (https=)
JP (3) JP7324193B2 (https=)
KR (2) KR20250024096A (https=)
CN (2) CN111386282B (https=)
AU (2) AU2018342246B2 (https=)
BR (1) BR112020006012A2 (https=)
CA (1) CA3077024A1 (https=)
CR (4) CR20240303A (https=)
DK (1) DK3688027T3 (https=)
EA (1) EA202090757A1 (https=)
ES (1) ES3056082T3 (https=)
FI (1) FI3688027T3 (https=)
IL (1) IL273515B2 (https=)
MA (1) MA50651A (https=)
MX (4) MX421596B (https=)
PL (1) PL3688027T3 (https=)
PT (1) PT3688027T (https=)
SG (1) SG11202002636PA (https=)
WO (1) WO2019067243A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058957T2 (hu) 2016-12-08 2022-10-28 Immatics Biotechnologies Gmbh Új T-sejt receptorok és velük végzett immunterápia
CA3080274A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
CA3144070A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
EP4208473A2 (en) * 2020-09-04 2023-07-12 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing r273c or y220c mutations in p53
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2022236050A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
US20250145950A1 (en) 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
WO2024206274A2 (en) 2023-03-27 2024-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
WO2025024648A2 (en) * 2023-07-25 2025-01-30 Memorial Sloan-Kettering Cancer Center T cell receptors targeting tp53 hotspot mutations and uses thereof
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途
WO2025226769A1 (en) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. T cell receptors targeting minor histocompatibility antigen lrh-1
WO2025250587A1 (en) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug-regulatable, inducible cytokine expression

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
AU2002316190B8 (en) * 2001-06-05 2009-01-29 Altor Bioscience Corporation p53 binding T cell receptor molecules and uses thereof
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
RU2721423C2 (ru) 2013-08-07 2020-05-19 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
EP3656864A1 (en) * 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
KR20160145802A (ko) * 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법
IL290655B2 (en) 2014-05-29 2024-05-01 Us Health Anti-human papillomavirus 16 E7 T-cell chelates
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
WO2016141169A1 (en) 2015-03-03 2016-09-09 Caris Mpi, Inc. Molecular profiling for cancer
US10544392B2 (en) * 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
TW202523682A (zh) 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
US11047011B2 (en) * 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use

Also Published As

Publication number Publication date
KR102762272B1 (ko) 2025-02-07
CR20240302A (es) 2024-11-07
MX2024005677A (es) 2024-06-11
CR20250153A (es) 2025-06-03
JP7573075B2 (ja) 2024-10-24
EP3688027B1 (en) 2025-09-10
JP7324193B2 (ja) 2023-08-09
IL273515B2 (en) 2026-03-01
MX2020003504A (es) 2020-09-14
CR20240303A (es) 2024-09-04
JP2021500010A (ja) 2021-01-07
PL3688027T3 (pl) 2026-04-07
JP7814467B2 (ja) 2026-02-16
MA50651A (fr) 2020-08-05
KR20250024096A (ko) 2025-02-18
MX2024005676A (es) 2024-06-11
EP4647442A2 (en) 2025-11-12
MX2024005678A (es) 2024-06-11
CA3077024A1 (en) 2019-04-04
MX421596B (es) 2025-03-14
CN111386282B (zh) 2024-09-06
IL273515A (en) 2020-05-31
CN118955684A (zh) 2024-11-15
SG11202002636PA (en) 2020-04-29
JP2025020145A (ja) 2025-02-12
IL273515B1 (en) 2025-11-01
JP2023159112A (ja) 2023-10-31
EP4647442A3 (en) 2026-03-04
DK3688027T3 (da) 2025-12-15
EA202090757A1 (ru) 2020-08-21
AU2024227695A1 (en) 2024-12-05
CN111386282A (zh) 2020-07-07
PT3688027T (pt) 2025-12-16
KR20200064110A (ko) 2020-06-05
AU2018342246A1 (en) 2020-04-16
WO2019067243A1 (en) 2019-04-04
US20200277352A1 (en) 2020-09-03
US20240270814A1 (en) 2024-08-15
ES3056082T3 (en) 2026-02-18
BR112020006012A2 (pt) 2020-10-06
US11939365B2 (en) 2024-03-26
CR20200170A (es) 2020-11-23
AU2018342246B2 (en) 2024-08-08
EP3688027A1 (en) 2020-08-05

Similar Documents

Publication Publication Date Title
FI3688027T3 (fi) Mutatoidun p53:n tunnistavia t-solureseptoreita
JP2023159112A5 (https=)
MX2024004610A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
JP2018535647A5 (https=)
CY1125601T1 (el) Υποδοχεις anti-kras-g12d κυτταρων τ
JP2019512242A5 (https=)
Lyngaa et al. T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors
JP2015525208A5 (https=)
FI3707159T3 (fi) Uusia muokattuja t-solureseptoreita ja niitä käyttävä immuuniterapia
JP2017536825A5 (https=)
Burton et al. The memory B cell response to influenza vaccination is impaired in older persons
JP2015535816A5 (https=)
MX2020005765A (es) Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
CL2021002997A1 (es) Construcción de reconocimiento de antígeno y su uso para el tratamiento de enfermedades proliferativas y para la detección in vitro de un cáncer (divisional de la solicitud 201901535)
SA518391109B1 (ar) Kras مستقبلات الخلايا التائية التي تميز hla-cw8 المطفرة المقيدة بـ
JP2016527230A5 (https=)
FI3332006T3 (fi) Uusia anti-PD-L1-vasta-aineita
Apavaloaei et al. Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer
RU2016124670A (ru) Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
CL2022002208A1 (es) Receptor de células t restringido por hla de la clase i contra ras con mutación
FI3448879T3 (fi) Claudin-6 -peptidejä
MX2022009825A (es) Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
Eisenberg et al. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells
US20260031189A1 (en) Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
Sohn et al. Measurement of CD8+ and CD4+ T cell frequencies specific for EBV LMP1 and LMP2a using mRNA-transfected DCs